We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Trial and error

6 June 2017 By Neil Unmack

A trial showed combining a new drug with the Swiss group’s Herceptin gave only a slight benefit to patients. That will make it harder to protect the blockbuster’s $7 bln of revenue from generic competitors. Roche could buy back shares, or rival drugmakers. Neither is cheap.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)